Literature DB >> 23053994

Association between SDF1-3'A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases.

Ferruh K Işman1, Canan Kucukgergin, Selçuk Daşdemir, Bedia Cakmakoglu, Oner Sanli, Sule Seckin.   

Abstract

In the present study, we aimed to investigate the association between SDF1-3'A and CXCR4 gene polymorphisms and the susceptibility and clinicopathological development of prostate cancer. SDF1-3'A and CXCR4 gene polymorphisms were assessed by polymerase chain reaction restriction-fragment length polymorphism (PCR-RFLP) in 149 healthy subjects and 152 patients with prostate cancer. There were no significant differences in the distributions of SDF-1 and CXCR4 genotypes between controls and prostate cancer patients. However, the patients with AA genotype of SDF1-3'A gene presented a higher risk for developing an advanced disease status as compared to patients with GG homozygotes (aOR = 2.02; 95 % CI = 1.05-3.90; P = 0.035). In addition, the distribution of AA genotype of SDF1-3'A gene was found significantly increased in the patients with bone metastasis in comparison to those without bone metastasis (aOR = 2.94; 95 % CI = 1.26-6.82; P = 0.012). On the other hand, CXCR4 gene polymorphism was not associated with the clinicopathological characteristics of prostate cancer. Our results suggest that SDF1-3'A and CXCR4 gene polymorphisms may not be risk factors for the susceptibility to prostate cancer. However, SDF1-3'A gene polymorphism may be associated with the progression and bone metastasis of prostate cancer in a Turkish men population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053994     DOI: 10.1007/s11033-012-2010-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  43 in total

1.  CXCL12-3' A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?

Authors:  Ana Coelho; Carmen Calçada; Raquel Catarino; Daniela Pinto; Graça Fonseca; Rui Medeiros
Journal:  Cancer Immunol Immunother       Date:  2005-09-06       Impact factor: 6.968

2.  Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells.

Authors:  Yan-Xi Sun; Ming Fang; Jianhua Wang; Carlton R Cooper; Kenneth J Pienta; Russell S Taichman
Journal:  Prostate       Date:  2007-01-01       Impact factor: 4.104

3.  Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line.

Authors:  Qinwen Wang; Xinwei Diao; Jianguo Sun; Zhengtang Chen
Journal:  Cell Biol Int       Date:  2011-09       Impact factor: 3.612

4.  Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression.

Authors:  Alex Soriano; Catalina Martínez; Felipe García; Montserrat Plana; Eduard Palou; Marylène Lejeune; Juan I Aróstegui; Elisa De Lazzari; Carmen Rodriguez; Alicia Barrasa; José I Lorenzo; José Alcamí; Jorge del Romero; José M Miró; José M Gatell; Teresa Gallart
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

5.  A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer.

Authors:  Eleftherios Vairaktaris; Antonis Vylliotis; Sofia Spyridonodou; Spyridoula Derka; Stavros Vassiliou; Emeka Nkenke; Christos Yapijakis; Zoe Serefoglou; Friedrich W Neukam; Efstratios Patsouris
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

6.  Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer.

Authors:  Takuya Akashi; Keiichi Koizumi; Koichi Tsuneyama; Ikuo Saiki; Yasuo Takano; Hideki Fuse
Journal:  Cancer Sci       Date:  2008-01-14       Impact factor: 6.716

7.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

Authors:  Roy Vergis; Catherine M Corbishley; Andrew R Norman; Jaclyn Bartlett; Sameer Jhavar; Michael Borre; Sara Heeboll; Alan Horwich; Robert Huddart; Vincent Khoo; Ros Eeles; Colin Cooper; Matthew Sydes; David Dearnaley; Chris Parker
Journal:  Lancet Oncol       Date:  2008-03-17       Impact factor: 41.316

8.  Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells.

Authors:  Aki Hanyu; Kiyotsugu Kojima; Kiyohiko Hatake; Kimie Nomura; Hironori Murayama; Yuichi Ishikawa; Satoshi Miyata; Masaru Ushijima; Masaaki Matsuura; Etsuro Ogata; Keiji Miyazawa; Takeshi Imamura
Journal:  Cancer Sci       Date:  2009-08-03       Impact factor: 6.716

9.  CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Authors:  Karen Brajão de Oliveira; Julie Massayo Maeda Oda; Julio Cesar Voltarelli; Thiago Franco Nasser; Mario Augusto Ono; Thiago Cezar Fujita; Tiemi Matsuo; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

10.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

View more
  10 in total

1.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

2.  Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population.

Authors:  Vibha Singh; Praveen Kumar Jaiswal; Rohit Kapoor; Rakesh Kapoor; Rama Devi Mittal
Journal:  Tumour Biol       Date:  2014-01-16

Review 3.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

Review 4.  Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer.

Authors:  Franziska Eckert; Karin Schilbach; Lukas Klumpp; Lilia Bardoscia; Efe Cumhur Sezgin; Matthias Schwab; Daniel Zips; Stephan M Huber
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

Review 5.  Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance.

Authors:  Sangita Sridharan; Cory M Howard; Augustus M C Tilley; Boopathi Subramaniyan; Amit K Tiwari; Randall J Ruch; Dayanidhi Raman
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

6.  Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.

Authors:  Claudio Festuccia; Andrea Mancini; Giovanni Luca Gravina; Alessandro Colapietro; Antonella Vetuschi; Simona Pompili; Luca Ventura; Simona Delle Monache; Roberto Iorio; Andrea Del Fattore; William Fogler; John Magnani
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

7.  The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants.

Authors:  Xiang Tong; Yao Ma; Huajiang Deng; Xixi Wang; Sitong Liu; Zhipeng Yan; Shifeng Peng; Hong Fan
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

Review 8.  CXC motif chemokine receptor 4 gene polymorphism and cancer risk.

Authors:  Yang Wu; Chun Zhang; Weizhang Xu; Jianzhong Zhang; Yuxiao Zheng; Zipeng Lu; Dongfang Liu; Kuirong Jiang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

9.  An Investigation of SDF1/CXCR4 Gene Polymorphisms in Autism Spectrum Disorder: A Family-Based Study.

Authors:  Tayfun Kara; İsmail Akaltun; Bedia Cakmakoglu; İlyas Kaya; Salih Zoroğlu
Journal:  Psychiatry Investig       Date:  2018-02-22       Impact factor: 2.505

10.  Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness.

Authors:  Sangita Sridharan; Megan Robeson; Diwakar Bastihalli-Tukaramrao; Cory M Howard; Boopathi Subramaniyan; Augustus M C Tilley; Amit K Tiwari; Dayanidhi Raman
Journal:  Front Oncol       Date:  2019-12-06       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.